Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4278424 | 0.99 | OPRD1 (0.49) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4281741 | 0.95 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4271316 | 0.92 | OPRD1 (0.50) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4283093 | 0.92 | OPRD1 (0.46) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4276783 | 0.90 | OPRD1 (0.45) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4278330 | 0.89 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4268937 | 0.89 | OPRD1 (0.49) | OPRD1KCNH2CYP2D6OPRK1 | |
| Hydrochloric Acid SCHEMBL4281080 | 0.88 | OPRD1 (0.46) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4413988 | 0.88 | OPRD1 (0.45) | OPRD1KCNH2CYP2D6FFAR4OPRK1 | |
| Hydrochloric Acid SCHEMBL4276947 | 0.87 | OPRD1 (0.45) | OPRD1KCNH2CYP2D6FFAR4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| CN-117440816-A | Modified MIR-135, conjugated forms thereof and uses thereof | 耶达研究及发展有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-10071163-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-09-11 | — | — | US | disclosed |
| EP-2560687-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | NLIFE THERAPEUTICS S L (ES) | 2017-05-24 | — | — | EP | disclosed |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LIMITED (CY) | 2016-08-18 | — | — | US | disclosed |
| US-9193969-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2015-11-24 | — | — | US | disclosed |
| EP-1841418-B1 | Glycine reuptake inhibitors for treating drug and alcohol dependence | MSD OSS BV (NL) | 2013-04-17 | — | — | EP | disclosed |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2012-12-20 | — | — | US | disclosed |
| US-20080051456-A1 | Glycine Reuptake Inhibitors for Treatment of Drug Dependence | MSD OSS B.V. (NL) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071163-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | OPRD1 739/4885KCNH2 3330/4885CYP2D6 4851/4885 |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | SLC6A2, SLC18A2, SLC1A1 | OPRD1 739/4885KCNH2 3330/4885CYP2D6 4851/4885 |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | OPRD1 4640/4885KCNH2 4853/4885CYP2D6 2646/4885 |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | OPRD1 739/4885KCNH2 3330/4885CYP2D6 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.